Monopar Therapeutics (MNPR)
(Delayed Data from NSDQ)
$0.63 USD
-0.03 (-4.49%)
Updated Apr 25, 2024 03:58 PM ET
After-Market: $0.64 +0.01 (1.99%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth D Momentum D VGM
Price, Consensus and EPS Surprise
MNPR 0.63 -0.03(-4.49%)
Will MNPR be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for MNPR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MNPR
Monopar Therapeutics (MNPR) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
All You Need to Know About Monopar Therapeutics (MNPR) Rating Upgrade to Buy
MNPR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Monopar Therapeutics Inc. (MNPR) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Monopar Therapeutics Inc. (MNPR) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Monopar Therapeutics (MNPR) Up On Soft Tissue Sarcoma Study Data
Other News for MNPR
Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting
Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings
Monopar files patent protecting its MNPR-101 radiopharma optimization findings
Monopar Therapeutics Advances Radiopharmaceuticals with New Patent
Monopar Therapeutics announces filing of patent protecting MNPR-101